Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia

Arsenic trioxide (ATO) mediates PML-RARA (promyelocytic leukemia–retinoic acid receptor-α) oncoprotein degradation via the proteasome pathway and this degradation appears to be critical for achieving cure in acute promyeloytic leukemia (APL). We have previously demonstrated significant micro-environ...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Leukemia
Autors principals: Ganesan, S, Alex, A A, Chendamarai, E, Balasundaram, N, Palani, H K, David, S, Kulkarni, U, Aiyaz, M, Mugasimangalam, R, Korula, A, Abraham, A, Srivastava, A, Padua, R A, Chomienne, C, George, B, Balasubramanian, P, Mathews, V
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2016
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5097069/
https://ncbi.nlm.nih.gov/pubmed/27560113
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2016.227
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars